Pharmaceutical composition containing FLT3 inhibitor and chemotherapeutic agent for treating acute myelogenous leukemia

Abstract

Provided are pharmaceutical compositions for the treatment of acute myelogenous leukemia (AML); and a method for treating acute myelogenous leukemia by using the pharmaceutical composition. The pharmaceutical composition comprises a therapeutically effective combination of: an Fms-like tyrosine kinase-3 (FLT3) inhibitor, or a pharmaceutically acceptable salt or solvate thereof; and a chemotherapeutic agent or a pharmaceutically acceptable salt or solvate thereof.

Description

technical field [0001] The present invention relates to pharmaceutical compositions for the treatment of acute myeloid leukemia comprising effective therapeutic compositions of Fms-like tyrosine kinase-3 (FLT3) inhibitors and chemotherapeutic agents; and methods of treatment using such compositions. Background technique [0002] Fms-like tyrosine kinase-3 (FLT3) is one of the most commonly mutated genes in acute myeloid leukemia (AML). Mutant FLT3 (mutant FLT3) refers to a mutation expressed in leukemia cells present in a subset of acute myeloid leukemia (AML) patients. Activating mutations in FLT3, such as intragenic tandem duplication (ITD) in the proximal domain, appear in about 25-30% of newly diagnosed AML cases (Patent Document 1). FLT3 mutation is known to occur in about one-third of acute myeloid leukemia (AML) patients (Non-Patent Document 1). [0003] Although several FLT3 inhibitors are clinically available, drug-resistant leukocytes have been observed in AML pa...

AI Technical Summary

Problems solved by technology

In addition, with conventional acute myeloid leukemia (AML) standard chemotherapy, targeting AML stem / progenitor cells is impossible, so the disease often recurs in patients, and thus there is a problem of limited long-term efficacy (Non-Patent Document 2)

Treatment of FLT3- AML patients with ITD mutations also exhibit poorer prognosis (Non-Patent Document 4)

Images